AMENDMENTS TO THE CLAIMS:

In the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended) A compound selected from the group represented by Formula

1:

$$R^2$$
 R^3
 R^4
 R^5
 R^a
 R^b
 R^c
 R^c

Formula I

where:

- U-V is -N(R⁶)-CR^eR^f-, -CR^eR^f-N(R⁶)-, -N(R⁶)-CR^eR^f-CR^gR^h, -CR^eR^f-N(R⁶)-CR^gR^h- or -CR^eR^f-CR^gR^h-N(R⁶)-;
- R^a, R^b, R^c, R^d, R^e, R^f, R^g and R^h are independently hydrogen, alkyl, aryl, aralkyl, heteroaryl, substituted alkyl, substituted aryl, substituted aralkyl or substituted heteroaryl;
- R¹, R², R³, and R⁴ are independently hydrogen, alkyl, alkoxy, halogen, cyano or substituted alkyl;
- R⁵ is <u>benzyl or substituted benzyl;</u> alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, substituted alkyl, substituted aryl, substituted aralkyl, substituted heteroaryl or substituted heteroaralkyl; and
- R⁶ is <u>benzoyl, substituted benzoyl, benzyl or substituted benzyl; hydrogen, acyl, alkyl, aryl, aralkyl, heteroaryl, substituted acyl, substituted alkyl, substituted aryl, substituted aralkyl or substituted heteroaryl;</u>

or a pharmaceutically acceptable salt or solvate thereof.

2. (Currently Amended) The compound of Claim 1, or a pharmaceutically acceptable salt thereof, where: comprising one or more of the following:

R¹, R², R³ and R⁴ are independently hydrogen, chloro, fluoro, methyl, methoxy, cyano or substituted lower alkyl;

R⁵ is aralkyl or substituted aralkyl;

Ra to Rh are independently hydrogen, lower alkyl or substituted lower alkyl;

U-V is -N(R⁶)-CR^eR^f-CR^gR^h, -CR^eR^f-N(R⁶)-CR^gR^h- or -CR^eR^f-CR^gR^h-N(R⁶)-;

R⁶ is <u>substituted benzyl or substituted benzoyl;</u> optionally substituted aralkyl or optionally substituted acyl; and

is an (R)-enantiomer.

3. (Currently Amended) The compound of Claim 2, or a pharmaceutically acceptable salt thereof, where: comprising one or more of the following:

R¹, R², R³ and R⁴ are independently hydrogen, chloro, fluoro, methyl, methoxy or cyano;

R⁵-is-benzyl or substituted benzyl;

no more than one of Ra to Rh is other than hydrogen;

U-V is -N(R⁶)-CR^eR^f-CR^gR^h- or -CR^eR^f-N(R⁶)-CR^gR^h-; and

R⁶ is optionally substituted <u>benzoyl.</u> acyl.

4. (Currently Amended) The compound of Claim 3 comprising one or more of the following:

A compound selected from the group represented by Formula 1:

$$R^2$$
 R^3
 R^4
 R^5
 R^6
 R^6
 R^6
 R^6

Formula I

where:

R¹, R², R³ and R⁴ are hydrogen, or three of R¹, R², R³ and R⁴ are hydrogen and the fourth is halo, methoxy, methyl or cyano;

R⁵ is benzyl;

Ra to Rh are hydrogen;

U-V is -N(R⁶)-CR^eR^f-CR^gR^h-; and

R⁶ is p-methyl-benzoyl;

or a pharmaceutically acceptable salt thereof.

- 5. (Currently Amended) The compound of Claim 4, or a pharmaceutically acceptable salt thereof, where: R¹, R² and R⁴ are hydrogen and R³ is hydrogen or chloro.
- 6. (Cancelled)
- 7. (Currently Amended) The compound of Claim 1, selected from:
- 3-benzyl-7-chloro-2-[1-(4-methyl-benzyl)-pyrrolidin-2-yl]-3*H*-quinazolin-4-one;
- 3-benzyl-7-chloro-2-[1-(4-methyl-benzoyl)-pyrrolidin-2-yl]-3*H*-quinazolin-4-one;
- 3-beznyl-7-chloro-2-[1-(4-methyl-benzoyl)-piperidin-2-yl]-3*H*-quinazolin-4-one;
- 3-beznyl-7-chloro-2-[1-(4-methyl-benzyl)-piperidin-3-yl]-3*H*-quinazolin-4-one;
- 3-beznyl-7-chloro-2-[1-(4-methyl-benzoyl)-piperidin-3-yl]-3H-quinazolin-4-one;
- 3-benzyl-7-chloro-2-[1-(4-methyl-benzyl)-piperidin-4-yl]-3H-quinazolin-4-one; and
- 3-benzyl-7-chloro-2-[1-(4-methyl-benzoyl)-piperidin-4-yl]-3*H*-quinazolin-4-one; or a pharmaceutically acceptable salt thereof.
- 8. (Currently Amended) The compound of Claim 7, or a pharmaceutically acceptable salt thereof, that is an (R)-enantiomer.
- 9. (Currently Amended) The compound of Claim 1, selected from: 3-benzyl-7-chloro-2-[1-(4-methyl-benzoyl)-pyrrolidin-2-yl]-3*H*-quinazolin-4-one;

- 3-benzyl-7-chloro-2-[1-(4-methyl-benzoyl)-piperidin-2-yl]-3*H*-quinazolin-4-one; 3-benzyl-7-chloro-2-[1-(4-methyl-benzoyl)-piperidin-3-yl]-3*H*-quinazolin-4-one; and 3-benzyl-7-chloro-2-[1-(4-methyl-benzoyl)-piperidin-4-yl]-3*H*-quinazolin-4-one; or a pharmaceutically acceptable salt thereof.
- 10. (Currently Amended) The compound of Claim 9, or a pharmaceutically acceptable salt thereof, that is an (R)-enantiomer.
- 11. (Currently Amended) The compound of Claim 1, selected from:
 3-benzyl-7-chloro-2-[1-(4-methyl-benzoyl)-piperidin-2-yl]-3*H*-quinazolin-4-one; and
 3-benzyl-7-chloro-2-[1-(4-methyl-benzoyl)-piperidin-3-yl]-3*H*-quinazolin-4-one[[,]]; or a pharmaceutically acceptable salt thereof.

 especially the (R) -enantiomers thereof.
- 12. (Currently Amended) The compound of Claim 11, or a pharmaceutically acceptable salt thereof, that is an (R)-enantiomer.
- 13. (Currently Amended) A pharmaceutical formulation comprising a pharmaceutical acceptable excipient and an effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof.
- 14.-27. (Cancelled)
- 28. (New) The compound of Claim 1, or a pharmaceutically acceptable salt thereof, where U-V is -N(R⁶)-CR^eR^f-CR^gR^h, -CR^eR^f-N(R⁶)-CR^gR^h- or -CR^eR^f-CR^gR^h-N(R⁶)-.
- 29. (New) The compound of Claim 28, or a pharmaceutically acceptable salt thereof, where U-V is -N(R⁶)-CR^eR^f-CR^gR^h- or -CR^eR^f-N(R⁶)-CR^gR^h-;.
- 30. (New) The compound of Claim 29, or a pharmaceutically acceptable salt thereof, where U-V is -N(R⁶)-CR^eR^f-CR^gR^h-.

- 31. (New) The compound of Claim 30, or a pharmaceutically acceptable salt thereof, where U-V is -N(R⁶)-CH₂-CH₂-.
- 32. (New) The compound of Claim 1, or a pharmaceutically acceptable salt thereof, where R¹, R², R³ and R⁴ are independently hydrogen, chloro, fluoro, methyl, methoxy, cyano or substituted lower alkyl.
- 33. (New) The compound of Claim 32, or a pharmaceutically acceptable salt thereof, where R¹, R², R³ and R⁴ are independently hydrogen, chloro, fluoro, methyl, methoxy or cyano.
- 34. (New) The compound of Claim 33, or a pharmaceutically acceptable salt thereof, where R^1 , R^2 , R^3 and R^4 are hydrogen.
- 35. (New) The compound of Claim 33, or a pharmaceutically acceptable salt thereof, where three of R¹, R², R³ and R⁴ are hydrogen and the fourth is halo, methoxy, methyl or cyano.
- 36 (New) The compound of Claim 33, or a pharmaceutically acceptable salt thereof, where R¹, R² and R⁴ are hydrogen and R³ is hydrogen or chloro.
- 37 (New) The compound of Claim 1, or a pharmaceutically acceptable salt thereof, where R⁵ is benzyl.
- 38. (New) The compound of Claim 1, or a pharmaceutically acceptable salt thereof, where R^a to R^h are independently hydrogen, lower alkyl or substituted lower alkyl.
- 39. (New) The compound of Claim 38, or a pharmaceutically acceptable salt thereof, where R^a to R^h are hydrogen.
- 40. (New) The compound of Claim 1, or a pharmaceutically acceptable salt thereof, where R⁶ is substituted benzyl or substituted benzyl.

- 41. (New) The compound of Claim 40, or a pharmaceutically acceptable salt thereof, where R⁶ is optionally substituted benzoyl.
- 42. (New) The compound of Claim 41, or a pharmaceutically acceptable salt thereof, where R⁶ is p-methyl-benzoyl.
- 43. (New) The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is an (R)-enantiomer.